We use cookies on our website. Carry on browsing if you’re happy with this or find out more

Infectious disease

Powerful discovery of therapeutics and vaccines

Infectious disease large

Our infectious disease work, in partnership with the Bill & Melinda Gates Foundation has built strong capabilities where we are developing product candidates that target pathogens that are predominant in the developing world.

Our IntelliSelect® Transgenic platforms, which contain a human antibody repertoire, provide an important surrogate for assessing normal human immune responses to infection. This allows us to test the efficacy of research-stage vaccines and to identify therapeutic antibodies targeting pathogens. With the Bill & Melinda Gates Foundation and their partners we have active programmes in Coronavirus, malaria, RSV, influenza, HIV, Bordetella pertussis and antimicrobial-resistant bacterial pathogens.

Alongside this work we are developing product candidates that target human viruses associated with transplantation and cancer.

We discover and develop antibody therapeutics to build a strong portfolio of assets

View our pipeline